Indeed, a correlation between high EZH2 expression and shorter overall survival was observed in patients with estrogen receptor (ER)-positive breast cancers, while low expression of LOXL4 and high level of miR-30d was associated with good prognosis (Figure S7B-C). This evidence concerns the gene EZH2 and breast carcinoma.